Geron mit Hammernews!! (Seite 70)
eröffnet am 18.03.03 18:26:10 von
neuester Beitrag 21.03.24 13:47:21 von
neuester Beitrag 21.03.24 13:47:21 von
Beiträge: 3.090
ID: 709.348
ID: 709.348
Aufrufe heute: 0
Gesamt: 213.087
Gesamt: 213.087
Aktive User: 0
ISIN: US3741631036 · WKN: 902213 · Symbol: GON
3,6780
EUR
0,00 %
0,0000 EUR
Letzter Kurs 02.05.24 Tradegate
Neuigkeiten
02.05.24 · Business Wire (engl.)  |
25.04.24 · Business Wire (engl.) |
18.04.24 · Business Wire (engl.) |
03.04.24 · Business Wire (engl.) |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,0720 | +77,11 | |
| 1,7850 | +42,80 | |
| 1,6600 | +32,80 | |
| 5,8700 | +26,24 | |
| 5,5500 | +26,14 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,5000 | -26,24 | |
| 0,6700 | -26,58 | |
| 6,4500 | -33,85 | |
| 2,1300 | -34,41 | |
| 3,1600 | -38,64 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 39.022.581 von optschraub am 26.02.10 17:46:33tja ,geht der kurs über 6$ scheinen die firmen die mit aktien bezahlt wurden dann auch mal bare münze sehn zu wollen verständlich... man hat ja auch so seine kosten am laufen.
die stückzahlen nehmen auch jedes jahr zu dadurch.verfolge jetzt schon ein paar jahre die aktie und kann an einen entscheidenen durchbruch kaum noch glauben...falls es doch noch klappt hofft man natürlich vorher drin zu sein...wie ist denn so die prognose ? wieviele jahre gehen noch ins land ...
die stückzahlen nehmen auch jedes jahr zu dadurch.verfolge jetzt schon ein paar jahre die aktie und kann an einen entscheidenen durchbruch kaum noch glauben...falls es doch noch klappt hofft man natürlich vorher drin zu sein...wie ist denn so die prognose ? wieviele jahre gehen noch ins land ...
Antwort auf Beitrag Nr.: 39.022.581 von optschraub am 26.02.10 17:46:33Das ist aber alles soweit im Rahmen. Geron ist mit den Stammzellen und der Antisense (GRN163L) auf einem wirklich hochtechnologischen Gebiet innerhalb der Biotechnologie unterwegs. Und teuer ist es auch noch. Aber wenn alles klappt, dann rollt der Rubel. Gerade der Erfolg der Antisense bei zahlreichen Biotechs (besonders Isis, Alnylam, Prosensa, Santaris), sollte mE nicht spurlos an Geron´s GRN163L vorbei gehen. Geron braucht dringend große Konzerne als Geldgeber.
Antwort auf Beitrag Nr.: 39.005.887 von Berliner_Landstreicher am 24.02.10 20:42:04na das hält sich ja in grenzen mit den verlusten...so schnell gewöhnen sich die investoren an das vierteljährliche debakel.
ich habe heute mal ein paar stücke ins depot gelegt.amiaktien sind bei mir angesagt...wenn die hedgefonds es schaffen den euro/dollar auf 1:1 zu bekommen verdient man dann mit...doppelt
ich habe heute mal ein paar stücke ins depot gelegt.amiaktien sind bei mir angesagt...wenn die hedgefonds es schaffen den euro/dollar auf 1:1 zu bekommen verdient man dann mit...doppelt
Antwort auf Beitrag Nr.: 39.005.622 von optschraub am 24.02.10 20:04:58Um den Cashburn zu drosseln, bezahlen die Brüder ja auch sehr häufig mit Aktien. Hab ich so exzessiv bei noch keener anderen Aktie gesehen. Und Dilution wird mE weiter gehen. Spätestens bei neuen GRN163L Studien muss der Wirkstoff von Lonza und Girindus teuer sythetisiert werden. An beide wurde beim letzten Mal Aktien im Millionenbereich (Stück) ausgeschüttet.
mal sehen wie morgen die zahlen ausfallen,ob der verlust verringert werden konnte...die verbrennen aber auch jeden monat mio $ das es nur so raucht.. bei verlustausweitung gibt es sicherlich den üblichen rutsch
Trading Spotlight
hallo allerseits,nach dem sturz von 6.60 auf 5,39 schein es gestern einige shorteindeckungen gegeben zu haben,hatte zumindest keine news gefunden als ursache für den anstieg,oder weiß jemand mehr?hier waren doch sonst immer genug stammzellenkundige vertreten in der diskussion,ist aber ruhig geworden hier...
Geron Announces Publication of Data on Its Telomerase Inhibitor in Glioblastoma
http://finance.yahoo.com/news/Geron-Announces-Publication-bw…
Bei GRN163L o. imetelstat müsste sich doch so langsam mal ne Partnerschaft finden lassen Jetzt sind se mit anderen GRN163L Studien teilw. in P2 und da wirds doch mal Zeit. Jedes Dorfbiotech mit einem interessanten Oligo-Wirkstoff findet einen Partner, warum nicht auch Geron? 2010 gehts weiter mit Studien.
http://finance.yahoo.com/news/Geron-Announces-Publication-bw…
Bei GRN163L o. imetelstat müsste sich doch so langsam mal ne Partnerschaft finden lassen Jetzt sind se mit anderen GRN163L Studien teilw. in P2 und da wirds doch mal Zeit. Jedes Dorfbiotech mit einem interessanten Oligo-Wirkstoff findet einen Partner, warum nicht auch Geron? 2010 gehts weiter mit Studien.
Scheint so als hätte man Stammzellen wiederentdeckt. Geron jedenfalls ist unter hohen Umsätzen aus dem Abwärtstrend der vergangennen Jahre heute scheinbar ausgebrochen.
Hoffen wir mal das es dabei bleibt
Just like investors need to swing for the fences once in a while, pharmaceutical companies sometimes have to look for the next big thing even if it's a long shot.
Enter Pfizer's (NYSE: PFE) license of a stem cell product, MultiStem, from tiny Athersys. And by tiny, I mean really tiny, as in $19-million-market-cap small before the announcement. That's well below my radar, so kudos to Pfizer for not blowing it off like the rest of us investors.
Having a big pharma partner validate its technology has caused Athersys to more than quadruple, as I write, over the last two days.
MultiStem is being tested in several conditions, but Pfizer's license is specifically for the treatment of inflammatory bowel disease (IBD), a group of conditions that includes ulcerative colitis and Crohn's disease. The license is only costing Pfizer $6 million up front because the technology is still relatively unproven, having not entered clinical trials for IBD yet. Athersys can get milestones of up to $105 million and royalties as the drug passes through clinical trials and is commercialized.
Pfizer will pay for the phase 1 and 2 trials. Then, if it gets that far, Athersys will have the option of co-developing the drug -- sharing profits and losses -- or letting Pfizer proceed on its own and take the milestones and royalty payments.
Unlike traditional stem cell companies like Geron (Nasdaq: GERN) that are developing stem cells to regenerate tissue, MultiStem uses donated bone marrow cells to produce a product that promotes healing of the tissue through cell signaling. Essentially it has a more drug-like profile as the stem cells are cleared from the body.
Stem cells aren't particularly new to large pharma. GlaxoSmithKline (NYSE: GSK) has a partnership with Harvard Stem Cell Institute and many companies, including Pfizer, Johnson & Johnson (NYSE: JNJ), Abbott Labs (NYSE: ABT), and sanofi-aventis (NYSE: SNY), teamed up to develop stem cells to help predict side effects.
But Pfizer seems to have taken a particular liking to stem cells, having established a unit to study them last year. If you're going to follow Pfizer's lead and invest in stem cell companies, I'd suggest you also follow its lead and keep your investments in stem cell technology to a very small fraction of your portfolio.
Hoffen wir mal das es dabei bleibt
Just like investors need to swing for the fences once in a while, pharmaceutical companies sometimes have to look for the next big thing even if it's a long shot.
Enter Pfizer's (NYSE: PFE) license of a stem cell product, MultiStem, from tiny Athersys. And by tiny, I mean really tiny, as in $19-million-market-cap small before the announcement. That's well below my radar, so kudos to Pfizer for not blowing it off like the rest of us investors.
Having a big pharma partner validate its technology has caused Athersys to more than quadruple, as I write, over the last two days.
MultiStem is being tested in several conditions, but Pfizer's license is specifically for the treatment of inflammatory bowel disease (IBD), a group of conditions that includes ulcerative colitis and Crohn's disease. The license is only costing Pfizer $6 million up front because the technology is still relatively unproven, having not entered clinical trials for IBD yet. Athersys can get milestones of up to $105 million and royalties as the drug passes through clinical trials and is commercialized.
Pfizer will pay for the phase 1 and 2 trials. Then, if it gets that far, Athersys will have the option of co-developing the drug -- sharing profits and losses -- or letting Pfizer proceed on its own and take the milestones and royalty payments.
Unlike traditional stem cell companies like Geron (Nasdaq: GERN) that are developing stem cells to regenerate tissue, MultiStem uses donated bone marrow cells to produce a product that promotes healing of the tissue through cell signaling. Essentially it has a more drug-like profile as the stem cells are cleared from the body.
Stem cells aren't particularly new to large pharma. GlaxoSmithKline (NYSE: GSK) has a partnership with Harvard Stem Cell Institute and many companies, including Pfizer, Johnson & Johnson (NYSE: JNJ), Abbott Labs (NYSE: ABT), and sanofi-aventis (NYSE: SNY), teamed up to develop stem cells to help predict side effects.
But Pfizer seems to have taken a particular liking to stem cells, having established a unit to study them last year. If you're going to follow Pfizer's lead and invest in stem cell companies, I'd suggest you also follow its lead and keep your investments in stem cell technology to a very small fraction of your portfolio.
Antwort auf Beitrag Nr.: 38.119.077 von Lotschka am 05.10.09 21:42:02http://www.newkerala.com/news/fullnews-23890.html
Experimental lung cancer drug may help treat brain, prostate cancer
Washington, Jan 4 : A drug, currently undergoing trials for breast and lung cancer, has also been found effective in treating brain cancer glioblastoma and prostate cancer, say researchers.
According to Dr. Jerry Shay, professor of cell biology, the drug''s actions, observed in isolated human cells in one trial and in rodents in the other, are especially encouraging because they attacked not only the bulk of the tumour cells but also the rare cancer stem cells that are believed to be responsible for most of a cancer''s growth.
In the brain cancer study, the drug could successfully cross the bloodstream into the brain, which is especially important because many drugs are not able to cross the blood-brain barrier.
"Because it attacks a mechanism that''s active in most cancers, it might prove to be widely useful, especially when combined with other therapies," said Shay.
The researchers focussed their study on telomeres, bits of DNA that help control how many times a cell divides. Telomeres are protective "caps" of DNA on the ends of chromosomes, the structures that contain the body''s genes. As long as telomeres are longer than a certain minimum length, a cell can keep dividing.
But telomeres shorten with each cell division, so a cell stops dividing once the telomeres are whittled down to that minimum.
In cancer cells, however, an enzyme called telomerase keeps rebuilding the telomeres, so the cell never receives the cue to stop dividing. In essence, they become immortal, dividing endlessly.
The experimental drug called imetelstat or GRN163L was found to block telomerase.
It is already in clinical trials as a potential treatment for breast and lung cancer, as well as for chronic lymphocytic leukemia.
Glioblastomas are the most common malignant brain tumours in adults. In the glioblastoma study Shay and his colleagues found that imetelstat blocked the action of telomerase in isolated tumour-initiating cells as well as the bulk of the tumour cells, eventually killing the cells.
Combining imetelstat with radiation and a standard chemotherapy drug made imetelstat even more effective.
In the prostate cancer study, the researchers isolated tumour-initiating cells from human prostate cancer cells. The cells showed significant telomerase activity. Imetelstat blocked the enzyme''s activity, and telomeres shortened greatly.
The glioblastoma study appears in Clinical Cancer Research. The prostate cancer study appears in the International Journal of Cancer.
Experimental lung cancer drug may help treat brain, prostate cancer
Washington, Jan 4 : A drug, currently undergoing trials for breast and lung cancer, has also been found effective in treating brain cancer glioblastoma and prostate cancer, say researchers.
According to Dr. Jerry Shay, professor of cell biology, the drug''s actions, observed in isolated human cells in one trial and in rodents in the other, are especially encouraging because they attacked not only the bulk of the tumour cells but also the rare cancer stem cells that are believed to be responsible for most of a cancer''s growth.
In the brain cancer study, the drug could successfully cross the bloodstream into the brain, which is especially important because many drugs are not able to cross the blood-brain barrier.
"Because it attacks a mechanism that''s active in most cancers, it might prove to be widely useful, especially when combined with other therapies," said Shay.
The researchers focussed their study on telomeres, bits of DNA that help control how many times a cell divides. Telomeres are protective "caps" of DNA on the ends of chromosomes, the structures that contain the body''s genes. As long as telomeres are longer than a certain minimum length, a cell can keep dividing.
But telomeres shorten with each cell division, so a cell stops dividing once the telomeres are whittled down to that minimum.
In cancer cells, however, an enzyme called telomerase keeps rebuilding the telomeres, so the cell never receives the cue to stop dividing. In essence, they become immortal, dividing endlessly.
The experimental drug called imetelstat or GRN163L was found to block telomerase.
It is already in clinical trials as a potential treatment for breast and lung cancer, as well as for chronic lymphocytic leukemia.
Glioblastomas are the most common malignant brain tumours in adults. In the glioblastoma study Shay and his colleagues found that imetelstat blocked the action of telomerase in isolated tumour-initiating cells as well as the bulk of the tumour cells, eventually killing the cells.
Combining imetelstat with radiation and a standard chemotherapy drug made imetelstat even more effective.
In the prostate cancer study, the researchers isolated tumour-initiating cells from human prostate cancer cells. The cells showed significant telomerase activity. Imetelstat blocked the enzyme''s activity, and telomeres shortened greatly.
The glioblastoma study appears in Clinical Cancer Research. The prostate cancer study appears in the International Journal of Cancer.
http://www.sciencedaily.com/releases/2010/01/100104041830.ht…
Experimental Drug Shows Promise Against Brain, Prostate Cancers
ScienceDaily (Jan. 4, 2010) — An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center have found in two preclinical studies.
The drug's actions, observed in isolated human cells in one trial and in rodents in the other, are especially encouraging because they attacked not only the bulk of the tumor cells but also the rare cancer stem cells that are believed to be responsible for most of a cancer's growth, said Dr. Jerry Shay, professor of cell biology and a senior co-author of both papers. The glioblastoma study appears in the January issue of Clinical Cancer Research. The prostate cancer study is available online in the International Journal of Cancer.
In the glioblastoma study, performed in mice, the drug also crossed from the bloodstream into the brain, which is especially important because many drugs are not able to cross the blood-brain barrier.
"Because it attacks a mechanism that's active in most cancers, it might prove to be widely useful, especially when combined with other therapies," said Dr. Shay.
Dr. Shay and his colleagues study telomeres, bits of DNA that help control how many times a cell divides. Telomeres are protective "caps" of DNA on the ends of chromosomes, the structures that contain the body's genes. As long as telomeres are longer than a certain minimum length, a cell can keep dividing. But telomeres shorten with each cell division, so a cell stops dividing once the telomeres are whittled down to that minimum.
In cancer cells, however, an enzyme called telomerase keeps rebuilding the telomeres, so the cell never receives the cue to stop dividing. In essence, they become immortal, dividing endlessly.
The drug used in these studies (imetelstat or GRN163L) blocks telomerase. It is already in clinical trials as a potential treatment for breast and lung cancer, as well as for chronic lymphocytic leukemia.
Glioblastomas are the most common malignant brain tumors in adults, according to the American Cancer Society. They are difficult to treat with drugs because blood vessels in the brain have tightly constructed walls that allow only a few substances to pass through.
The researcher focused on cells called tumor-initiating cells. Some researchers believe that tumors contain a small subset of initiating cells -- or cancer stem cells -- that are able to initiate and drive tumors and that are often resistant to radiation therapy and chemotherapy.
In the glioblastoma study, Dr. Shay and his colleagues found that imetelstat blocked the action of telomerase in isolated tumor-initiating cells as well as the bulk of the tumor cells, eventually killing the cells. Combining imetelstat with radiation and a standard chemotherapy drug made imetelstat even more effective. When the researchers implanted human tumor-initiating cells into rodents, they found that imetelstat was able to enter brain tissue and inhibit telomerase activity.
In the prostate cancer study, the researchers isolated tumor-initiating cells from human prostate cancer cells. The cells showed significant telomerase activity. Imetelstat blocked the enzyme's activity, and telomeres shortened greatly.
Other UT Southwestern researchers involved in the glioblastoma study were lead author Dr. Calin Marian, postdoctoral researcher in cell biology; Dr. Steve Cho, postdoctoral researcher in neurology; graduate student Brian McEllin; Dr. Elizabeth Maher, associate professor of internal medicine; Dr. Kimmo Hatanpaa, assistant professor of pathology; Dr. Christopher Madden, associate professor of neurological surgery; Dr. Bruce Mickey, professor of neurological surgery; Dr. Woodring Wright, professor of cell biology; and co-senior author Dr. Robert Bachoo, assistant professor of neurology.
Other UT Southwestern researchers involved in the prostate cancer study were lead author Dr. Marian and Dr. Wright.
Geron Corporation, which manufactures GRN163L under the name imetelstat, provided the drug for both studies. The glioblastoma study was supported by the National Institutes of Health. The prostate cancer study was supported by a Department of Defense Prostate Cancer Training Award and the Southland Financial Corporation.
Experimental Drug Shows Promise Against Brain, Prostate Cancers
ScienceDaily (Jan. 4, 2010) — An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center have found in two preclinical studies.
The drug's actions, observed in isolated human cells in one trial and in rodents in the other, are especially encouraging because they attacked not only the bulk of the tumor cells but also the rare cancer stem cells that are believed to be responsible for most of a cancer's growth, said Dr. Jerry Shay, professor of cell biology and a senior co-author of both papers. The glioblastoma study appears in the January issue of Clinical Cancer Research. The prostate cancer study is available online in the International Journal of Cancer.
In the glioblastoma study, performed in mice, the drug also crossed from the bloodstream into the brain, which is especially important because many drugs are not able to cross the blood-brain barrier.
"Because it attacks a mechanism that's active in most cancers, it might prove to be widely useful, especially when combined with other therapies," said Dr. Shay.
Dr. Shay and his colleagues study telomeres, bits of DNA that help control how many times a cell divides. Telomeres are protective "caps" of DNA on the ends of chromosomes, the structures that contain the body's genes. As long as telomeres are longer than a certain minimum length, a cell can keep dividing. But telomeres shorten with each cell division, so a cell stops dividing once the telomeres are whittled down to that minimum.
In cancer cells, however, an enzyme called telomerase keeps rebuilding the telomeres, so the cell never receives the cue to stop dividing. In essence, they become immortal, dividing endlessly.
The drug used in these studies (imetelstat or GRN163L) blocks telomerase. It is already in clinical trials as a potential treatment for breast and lung cancer, as well as for chronic lymphocytic leukemia.
Glioblastomas are the most common malignant brain tumors in adults, according to the American Cancer Society. They are difficult to treat with drugs because blood vessels in the brain have tightly constructed walls that allow only a few substances to pass through.
The researcher focused on cells called tumor-initiating cells. Some researchers believe that tumors contain a small subset of initiating cells -- or cancer stem cells -- that are able to initiate and drive tumors and that are often resistant to radiation therapy and chemotherapy.
In the glioblastoma study, Dr. Shay and his colleagues found that imetelstat blocked the action of telomerase in isolated tumor-initiating cells as well as the bulk of the tumor cells, eventually killing the cells. Combining imetelstat with radiation and a standard chemotherapy drug made imetelstat even more effective. When the researchers implanted human tumor-initiating cells into rodents, they found that imetelstat was able to enter brain tissue and inhibit telomerase activity.
In the prostate cancer study, the researchers isolated tumor-initiating cells from human prostate cancer cells. The cells showed significant telomerase activity. Imetelstat blocked the enzyme's activity, and telomeres shortened greatly.
Other UT Southwestern researchers involved in the glioblastoma study were lead author Dr. Calin Marian, postdoctoral researcher in cell biology; Dr. Steve Cho, postdoctoral researcher in neurology; graduate student Brian McEllin; Dr. Elizabeth Maher, associate professor of internal medicine; Dr. Kimmo Hatanpaa, assistant professor of pathology; Dr. Christopher Madden, associate professor of neurological surgery; Dr. Bruce Mickey, professor of neurological surgery; Dr. Woodring Wright, professor of cell biology; and co-senior author Dr. Robert Bachoo, assistant professor of neurology.
Other UT Southwestern researchers involved in the prostate cancer study were lead author Dr. Marian and Dr. Wright.
Geron Corporation, which manufactures GRN163L under the name imetelstat, provided the drug for both studies. The glioblastoma study was supported by the National Institutes of Health. The prostate cancer study was supported by a Department of Defense Prostate Cancer Training Award and the Southland Financial Corporation.
Durchsuchen
